Astellas Pharma Patent-Cliff Exposure & CMS Drug Spending Portfolio
Astellas Pharma (Northbrook, IL): 17 reconciled FDA prescription therapies (96.0% 2025 to 2030 cliff risk), $6.40B 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Northbrook, IL |
| Reconciled FDA Portfolio Therapies | 17 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 96.0% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $6.40B |
| 2024 Medicare Part D Spend | $5.99B |
| 2024 Medicaid Spend | $406.6M |
| California HCAI SB 17 Filings | 11 WAC filings (max 25.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.